Overview
Sunshine Holdings is a diversified group spanning healthcare, consumer products and agribusiness. The September update showed strong sales and profit growth, led by a substantially better second quarter after a weaker June quarter.
The improvement needs to be read alongside softer year-on-year gross and operating margins, a meaningful minority interest in group profit, and a dividend payout above the latest audited year's earnings.
Price performance
SUN closed at LKR 29.00 on 2 November 2026. It fell 2.4% over three months while the ASPI fell 4.9%, so it held up better than the market over that window; over one year, however, SUN fell 13.4% against a 12.1% ASPI decline.
The share sits 17.9% of the way up its 52-week range, close to the low rather than the high. Sixty-day volatility was 42.5% below its own one-year norm and recent volume was 59.5% below its 60-day average, indicating quieter trading rather than unusually active price movement.
The record shows two falls of 15% or more in three years, the deepest 31%, which has not yet recovered. Median daily turnover was LKR 6.3 million; a LKR 1 million order is about 16% of what trades on a typical day, a noticeable part of a day's trading.
Valuation
At 18.7 times earnings, the shares price each rupee of trailing profit at LKR 18.70. The P/B of 2.79 means LKR 2.79 is paid for each rupee of net assets, versus a sector median of 1.14 and an 85th-percentile P/B among 21 diversified holdings. The latest audited ROE was 15.3%, which provides some operating justification for paying above book, but the premium remains substantial.
The 6.2% dividend yield is in the 94th percentile of the sector, while the payout rose to LKR 1.80 in FY2026 from LKR 0.98 in FY2025. Both P/E and P/B are more expensive than at 13 of its last 14 year-ends, so the current valuation is elevated against Sunshine's own record as well as against peers.
A buyer at this price is relying materially on the latest quarter: it supplied 41.9% of trailing EPS. If that quarter had earned its year-ago net margin, the same price would stand at 20.9 times earnings rather than 18.7 times.
News and sentiment
Coverage has been unusually heavy, with 10 articles in the past 30 days against a normal monthly baseline of 4.0. Of 16 material articles over 90 days, 12 were positive, three negative and one neutral, although the tone of coverage is not evidence of company value.
Results reported on 2 November put September-quarter profit attributable to owners at LKR 1.45 billion, up 80.3%, while revenue rose 32.0% to LKR 21.6 billion. The same reporting highlighted pressure from regulated pharmaceutical price cuts and a weaker rupee.
Sunshine and Zydus have committed over USD 20 million to a 50:50 pharmaceutical manufacturing venture targeting commercial operations in 2028. The announcement gives no production capacity, sales or profit estimate, so its eventual earnings contribution cannot yet be sized. Sunshine Healthcare also acquired a 21.92% Doc990 stake for LKR 410.8 million, extending its healthcare presence into digital services.
Financials
September-quarter revenue rose 32.0% year-on-year and group net profit rose 76.6%, while operating profit grew 27.5%. The reported LKR 1.45 billion attributable profit is lower than group net profit of LKR 2.3 billion because LKR 880 million of the quarter's profit belonged to minority shareholders rather than to Sunshine ordinary shareholders.
Gross margin was 29.1% versus 32.1% a year earlier, operating margin was 16.8% versus 17.4%, and net margin was 10.8% versus 8.1%. Gross margin was the worst of seven comparable September quarters, while operating margin was among the worst at sixth of seven. September has nevertheless been Sunshine's strongest quarter for operating margin on average over the six complete years on record, so the relevant comparison is with prior Septembers rather than mixed quarters.
The net-margin improvement came despite weaker operating margins because below-the-line costs fell to LKR 1.3 billion from LKR 1.5 billion. Total equity rose to LKR 28.6 billion from LKR 27.3 billion a year earlier, while the share count remained broadly unchanged at 2.0 billion, so the reported profit growth was not mechanically created by a change in ordinary shares.
Risks
The most immediate financial risk is dividend coverage. FY2026 dividends equalled 116.1% of earnings and dividend cover was 0.86 times, meaning the audited year's profit did not fully fund the distribution. The upcoming LKR 0.50 first interim dividend reinforces the income case, but not the evidence of full earnings coverage.
Margin pressure is the main operating risk. September gross margin was the weakest of seven comparable September quarters, and healthcare accounts for 57% of reported segment revenue. Company reporting cited regulated pharmaceutical price cuts, while the wider healthcare backdrop remains shaped by procurement and regulatory reform; neither backdrop item establishes a direct financial effect on Sunshine.
Balance-sheet risk is present but contained by current earnings. Gearing was 47.8%, meaning debt equalled roughly 48 cents for each rupee of equity attributable to owners, with total debt of LKR 9.5 billion. Interest cover was 12.94 times, meaning operating profit covered the interest bill almost thirteen times. The current ratio was 1.73 times, or LKR 1.73 of short-term assets, including inventories and receivables, for each rupee of bills due within a year. FY2026 cash conversion was 0.84 times, so not all operating profit arrived as operating cash.
Outlook
As at 2 November 2026, the next company-specific test is the December 2026 interim filing, expected between 31 January and 14 February 2027. It will supersede the September figures and show whether the strong reported first-half revenue and attributable-profit growth continued after the September seasonal high for operating margin.
The LKR 0.50 first interim dividend has a confirmed ex-date of 10 November 2026 and payment date of 30 November 2026; only a buyer before the ex-date receives it. As at 2 November, the Zydus venture remained a longer-dated manufacturing project targeting 2028, and the available data does not disclose enough operating terms to judge its revenue or profit contribution.